Tositumomab/iodine-131 tositumomab (Bexxar) is a radioimmunotherapeutic agent in development for patients with low-grade or transformed non-Hodgkin’s lymphoma (NHL). This analysis focuses
R. Stagg
Advertisement
Articles by R. Stagg
Iodine-131 tositumomab (Bexxar) is a new radioimmunotherapy in development for the treatment of patients with low-grade or transformed low-grade non-Hodgkin’s lymphoma. The data from five phase I-III studies, which enrolled patients with low-
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Grants Priority Review to T-DXd in HER2+ Early Breast Cancer
2
FDA Issues CRL for Retifanlimab/Chemotherapy in Metastatic NSCLC
3
Rolling NDA Submission Completed for Zipalertinib in EGFR+ NSCLC
4
Exploring Optimal Radiotherapy Strategies in High-Risk Prostate Cancer
5